Previous 10 | Next 10 |
Aimed at providing greater access to faster and earlier diagnosis for people who may have a genetic mutation linked to WHIM syndrome and severe congenital neutropenia, X4 Pharmaceuticals ( XFOR +2.6% ) will partner with Invitae ( NVTA -1.4% ) to offer free-of-charge genetic testin...
Genetic testing to enable improved patient diagnoses and provide valuable disease-specific genetic insights for X4 clinical development of novel therapies X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeu...
SAN FRANCISCO , June 12, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of ID YOUR IRD, an initiative with Spark Therapeutics to offer genetic testing at no charge to patients suspected by their healthcare providers of havi...
The following slide deck was published by Invitae Corporation in conjunction with this Read more ...
SAN FRANCISCO , June 3, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leader in medical genetics, today announced the availability of its new service for consumers, which makes it easier for consumers to order and receive the same high-quality, medical genetic testing from Invitae...
SAN FRANCISCO , May 31, 2019 /PRNewswire/ -- Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, will present data that underscore the clinical utility of comprehensive genetic information for patients with breast, colorectal, prostate and pancreatic cancer t...
Aimed at identifying suitable patients for RAVICTI (glycerol phenylbutyrate) Oral Liquid, Horizon Therapeutics ( HZNP -2.3% ) launches a free-of-charge urea cycle disorder (UCD) genetic testing program with Invitae ( NVTA -2% ). More news on: Horizon Therapeutics Public Limited Compa...
-- New program improves access and speed to receiving a diagnosis for people and extended family members who may be living with Urea Cycle Disorders -- Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae Corporation (NYSE: NVTA) today announced a new urea cycle disorde...
SAN FRANCISCO , May 22, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George , co-founder and chief executive officer of Invitae will present at the 2019 William Blair Growth Stock Conference on Wednesday, Jun...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...